Targeting Dysregulated Lipid Metabolism in Cancer with Pharmacological Inhibitors

Metabolic plasticity is recognised as a hallmark of cancer cells, enabling adaptation to microenvironmental changes throughout tumour progression. A dysregulated lipid metabolism plays a pivotal role in promoting oncogenesis. Oncogenic signalling pathways, such as PI3K/AKT/mTOR, JAK/STAT, Hippo, and...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-04, Vol.16 (7), p.1313
Main Authors: Gupta, Amogh, Das, Dipanwita, Taneja, Reshma
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
AKT protein
Amino acids
Cancer
Carbon
Cholesterol
Drug therapy
Endoplasmic reticulum
Energy
Enzymes
Epigenetic inheritance
Epigenetics
Fatty acids
Glycerol
High density lipoprotein
Homeostasis
Hormones
Immunosuppressive agents
Kinases
Lipid metabolism
Lipids
Lipoproteins
Liver
Membrane lipids
Metabolism
Metastases
Metastasis
Mitochondria
NF-κB protein
Oxidation
Oxidative stress
Physiological aspects
Physiology
Proteins
Regulation
Signal transduction
Stem cells
TOR protein
Tumor microenvironment
Tumorigenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolic plasticity is recognised as a hallmark of cancer cells, enabling adaptation to microenvironmental changes throughout tumour progression. A dysregulated lipid metabolism plays a pivotal role in promoting oncogenesis. Oncogenic signalling pathways, such as PI3K/AKT/mTOR, JAK/STAT, Hippo, and NF-kB, intersect with the lipid metabolism to drive tumour progression. Furthermore, altered lipid signalling in the tumour microenvironment contributes to immune dysfunction, exacerbating oncogenesis. This review examines the role of lipid metabolism in tumour initiation, invasion, metastasis, and cancer stem cell maintenance. We highlight cybernetic networks in lipid metabolism to uncover avenues for cancer diagnostics, prognostics, and therapeutics.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16071313